270 related articles for article (PubMed ID: 15653657)
1. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs.
Pauwels S; Barone R; Walrand S; Borson-Chazot F; Valkema R; Kvols LK; Krenning EP; Jamar F
J Nucl Med; 2005 Jan; 46 Suppl 1():92S-8S. PubMed ID: 15653657
[TBL] [Abstract][Full Text] [Related]
2. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
3. Dosimetry of internal emitters.
Sgouros G
J Nucl Med; 2005 Jan; 46 Suppl 1():18S-27S. PubMed ID: 15653648
[TBL] [Abstract][Full Text] [Related]
4. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.
Barone R; Borson-Chazot F; Valkema R; Walrand S; Chauvin F; Gogou L; Kvols LK; Krenning EP; Jamar F; Pauwels S
J Nucl Med; 2005 Jan; 46 Suppl 1():99S-106S. PubMed ID: 15653658
[TBL] [Abstract][Full Text] [Related]
5. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.
de Jong M; Breeman WA; Bernard BF; Bakker WH; Visser TJ; Kooij PP; van Gameren A; Krenning EP
J Nucl Med; 2001 Dec; 42(12):1841-6. PubMed ID: 11752083
[TBL] [Abstract][Full Text] [Related]
6. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy.
Shen S; Meredith RF; Duan J; Macey DJ; Khazaeli MB; Robert F; LoBuglio AF
J Nucl Med; 2002 Sep; 43(9):1245-53. PubMed ID: 12215566
[TBL] [Abstract][Full Text] [Related]
7. Dosimetry in Peptide radionuclide receptor therapy: a review.
Cremonesi M; Ferrari M; Bodei L; Tosi G; Paganelli G
J Nucl Med; 2006 Sep; 47(9):1467-75. PubMed ID: 16954555
[TBL] [Abstract][Full Text] [Related]
8. Implementation and evaluation of patient-specific three-dimensional internal dosimetry.
Kolbert KS; Sgouros G; Scott AM; Bronstein JE; Malane RA; Zhang J; Kalaigian H; McNamara S; Schwartz L; Larson SM
J Nucl Med; 1997 Feb; 38(2):301-8. PubMed ID: 9025759
[TBL] [Abstract][Full Text] [Related]
9. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
[TBL] [Abstract][Full Text] [Related]
10. Canine anatomic phantom for preclinical dosimetry in internal emitter therapy.
Padilla L; Lee C; Milner R; Shahlaee A; Bolch WE
J Nucl Med; 2008 Mar; 49(3):446-52. PubMed ID: 18287264
[TBL] [Abstract][Full Text] [Related]
11. Hepatic structural dosimetry in (90)Y microsphere treatment: a Monte Carlo modeling approach based on lobular microanatomy.
Gulec SA; Sztejnberg ML; Siegel JA; Jevremovic T; Stabin M
J Nucl Med; 2010 Feb; 51(2):301-10. PubMed ID: 20080888
[TBL] [Abstract][Full Text] [Related]
12. Influence of total-body mass on the scaling of S-factors for patient-specific, blood-based red-marrow dosimetry.
Traino AC; Ferrari M; Cremonesi M; Stabin MG
Phys Med Biol; 2007 Sep; 52(17):5231-48. PubMed ID: 17762083
[TBL] [Abstract][Full Text] [Related]
13. Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy.
Konijnenberg M; Melis M; Valkema R; Krenning E; de Jong M
J Nucl Med; 2007 Jan; 48(1):134-42. PubMed ID: 17204710
[TBL] [Abstract][Full Text] [Related]
14. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.
Wessels BW; Konijnenberg MW; Dale RG; Breitz HB; Cremonesi M; Meredith RF; Green AJ; Bouchet LG; Brill AB; Bolch WE; Sgouros G; Thomas SR
J Nucl Med; 2008 Nov; 49(11):1884-99. PubMed ID: 18927342
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive dose reconstruction methodology for former rocketdyne/atomics international radiation workers.
Boice JD; Leggett RW; Ellis ED; Wallace PW; Mumma M; Cohen SS; Brill AB; Chadda B; Boecker BB; Yoder RC; Eckerman KF
Health Phys; 2006 May; 90(5):409-30. PubMed ID: 16607174
[TBL] [Abstract][Full Text] [Related]
16. Dosimetry in radionuclide therapies with 90Y-conjugates: the IEO experience.
Cremonesi M; Ferrari M; Chinol M; Bartolomei M; Stabin MG; Sacco E; Fiorenza M; Tosi G; Paganelli G
Q J Nucl Med; 2000 Dec; 44(4):325-32. PubMed ID: 11302260
[TBL] [Abstract][Full Text] [Related]
17. Dosimetric comparison between 2-dimensional radiation therapy and intensity modulated radiation therapy in treatment of advanced T-stage nasopharyngeal carcinoma: to treat less or more in the planning organ-at-risk volume of the brainstem and spinal cord.
Chau RM; Teo PM; Kam MK; Leung SF; Cheung KY; Chan AT
Med Dosim; 2007; 32(4):263-70. PubMed ID: 17980826
[TBL] [Abstract][Full Text] [Related]
18. Systemic and locoregional dosimetry in receptor radionuclide therapy with peptides.
Cremonesi M; Ferrari M; Bodei L; Tosi G; Paganelli G
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):288-95. PubMed ID: 17043626
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous beam geometry and intensity map optimization in intensity-modulated radiation therapy.
Lee EK; Fox T; Crocker I
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):301-20. PubMed ID: 16289912
[TBL] [Abstract][Full Text] [Related]
20. Overview of dosimetry for Systemic Targeted Radionuclide Therapy (STaRT).
Wessels BW; Syh JH; Meredith RF
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S39-45. PubMed ID: 16979438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
